ClinicalTrials.gg
RecruitingNCT07379099INEPPSUpdated Jan 30, 2026

Implementation of the Personalized Care Plan (PCP) Proposed at the End of Step 2 of the ICOPE Program

An observational study in Frailty and Frailty at Older Adults, sponsored by MSPU de Pins-Justaret. Recruiting at 1 site in France. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by MSPU de Pins-Justaret · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Frailty with a site in France — 23 open to participants now, 25 under way, none of them phase 3. Frailty · France.

Planned enrollment
11th of 32
600 · median 200
Started
2024
with 5 others
Observational
32 of 59
14 open now
Primary completion
2027-06
later than 11 of 24 live
Registered
53rd of 59
by date

Among the 59 studies in Frailty with a site in France, this one is the 11th largest by planned enrollment of the 32 observational ones that give a count, is one of 6 that started in 2024, is one of 32 observational ones, reaches primary completion later than 11 of the 24 other live ones, and was the 53rd registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

23 of the 59 studies in Frailty with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Frailty with a site in France, or all of them as a file.
02

Study summary

The ICOPE (Integrated Care for the Elderly) program is based on an integrated approach including a personalized care plan (PCP). Negotiation methods with the patient and interprofessional cooperation could be key elements in the success of this program. The main objective is to evaluate the feasibility of the implementation of the ICOPE program on the number and content of the PCP carried out at 1 year

03

Conditions studied

  • Frailty
  • Frailty at Older Adults

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Older adults aged 60 years and above, functionally independent

Eligibility criteria

Inclusion Criteria:

  • Age ≥ 60 years
  • ADL ≥ 5.5
  • Affiliated or beneficiary of a social security scheme or equivalent.
  • having completed a STEP 2 ICOPE
  • not opposed to the collection of their data
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Proportion of PCP completed

    Proportion of personalized care plan (PCP) completed

    Time frame: At 12 months

07

Study locations

1 of 1 sites recruiting
  • Maison de santé des Fontaines
    Toulouse, 31300, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jun 2027, 30 months after the start.

Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 30 months is close to that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Jan 30, 2026
StartActual
Dec 1, 2024
Primary completionEst.
Jun 1, 2027
CompletionEst.
Apr 1, 2028
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07379099
Lead sponsor
MSPU de Pins-Justaret
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Dec 1, 2024
Primary completion
Jun 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Jan 30, 2026

Study contacts

Bruno Chicoulaa
Contact
bruno1.chicoulaa1@dumg-toulouse.fr
0033661614449

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion